標靶治療市場規模、佔有率和成長分析（按類型、應用、分銷管道和地區）- 產業預測 2025-2032

2023 年全球標靶治療市場規模價值 732 億美元，預計將從 2024 年的 752.5 億美元成長到 2032 年的 938.5 億美元，預測期內（2025-2032 年）的複合年成長率為 2.8%。

由於單株抗體日益普及和生物技術的投資的增加，全球生技藥品和標靶治療市場正在快速成長。這些標靶治療可有效抑制癌細胞增殖，並被定位為腫瘤學的主要治療藥物。網上藥局的成長預計將促進這些治療藥物的銷售。此外，政府加大對醫療基礎建設的財政支持力度預計也將為市場擴張做出巨大貢獻。到2040年，全球需要針對性治療的病例數預計將達到2,840萬人。此外，大眾對可用治療方法的認知不斷提高也推動了市場的成長。然而，挑戰仍然存在，因為標靶治療相關的副作用可能會阻礙市場的整體進步。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

標靶治療藥物市場規模（按類型和複合年成長率） (2025-2032)

• 市場概況
• 單株抗體
  • 血管新生抑制劑
  • HER-2標靶藥物
  • 抗CD20單株抗體
• 小分子
  • 蛋白酪氨酸激酶抑制劑
  • mTOR 抑制劑
  • PARP 抑制劑

標靶治療藥物市場規模（依應用分類）及複合年成長率（2025-2032）

• 市場概況
• 乳癌
• 大腸直腸癌
• 白血病
• 肺癌
• 淋巴瘤
• 多發性硬化症
• 腎癌
• 濕性老齡化黃斑部病變
• 其他（卵巢癌、輸卵管癌、攝護腺癌、胰臟癌）

標靶治療藥物市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

標靶治療藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Roche（Switzerland）
• Novartis（Switzerland）
• Pfizer（USA）
• Merck & Co.（USA）
• Bristol-Myers Squibb（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Sanofi（France）
• Bayer（Germany）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie（USA）
• Takeda Pharmaceutical（Japan）
• Gilead Sciences（USA）
• Biogen（USA）
• Regeneron Pharmaceuticals（USA）
• Celgene（USA）（Acquired by Bristol-Myers Squibb）
• Incyte（USA）

結論和建議

Global Targeted Therapeutics Market size was valued at USD 73.2 billion in 2023 and is poised to grow from USD 75.25 billion in 2024 to USD 93.85 billion by 2032, growing at a CAGR of 2.8% during the forecast period (2025-2032).

The global market for biologics and targeted therapeutics is experiencing rapid growth, driven by the increasing popularity of monoclonal antibodies and rising investments in biotechnology. These targeted therapies effectively inhibit tumor cell proliferation, positioning them as leading treatments in oncology. Anticipated growth in online pharmacies is expected to enhance the sales of these therapeutic drugs. Additionally, heightened government financial support aimed at advancing healthcare infrastructure will significantly contribute to market expansion. By 2040, global cases of targeted therapeutic needs are projected to reach 28.4 million. Furthermore, growing awareness among the population about available treatments is also propelling market growth. However, challenges remain, as side effects related to targeted therapies could hinder overall market progress.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Therapeutics Market Segments Analysis

Global Targeted Therapeutics Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Monoclonal Antibodies and Small Molecule. Based on Application, the market is segmented into Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, Renal Cancer, Wet Age-related Macular Degeneration and Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer). Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Therapeutics Market

The Global Targeted Therapeutics market is primarily driven by the rising incidence of cancer coupled with the growing disposable income of individuals. As cancer rates continue to escalate worldwide, there is an increasing demand for innovative treatment options that offer more precise targeting of cancer cells, thus providing better outcomes for patients. Additionally, as disposable incomes rise, more patients are able to afford advanced therapies and medications, fueling the market's growth. This combination of heightened cancer prevalence and improved economic conditions creates a favorable environment for the expansion of targeted therapeutics, ultimately enhancing patient care and treatment accessibility.

Restraints in the Global Targeted Therapeutics Market

The global targeted therapeutics market faces several constraints, particularly related to the side effects associated with targeted therapies and drugs. These adverse effects can vary in severity and may include reactions that impact a patient's quality of life, leading to increased discontinuation rates and reluctance among healthcare providers to prescribe these treatments. Furthermore, the complexity of managing these side effects often requires additional resources, complicating care and potentially driving up healthcare costs. As a result, these challenges can hinder market growth and limit the overall adoption of targeted therapeutics in various therapeutic areas.

Market Trends of the Global Targeted Therapeutics Market

The global targeted therapeutics market is experiencing significant growth, driven by strategic collaborations, acquisition activities, and innovative product launches among major players. Companies are focusing on expansion strategies to enhance their therapeutic offerings, with a notable push in developing complement-targeted therapies to address various diseases. For instance, PubMed Inc.'s release of upgraded therapies showcases a commitment to improving treatment efficacy and addressing complex pathological conditions. This trend indicates a robust pipeline of novel therapies aimed at personalization and precision medicine, positioning the market for sustained growth as demand for tailored treatment options continues to rise globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
  • Angiogenesis Inhibitors
  • HER-2 Targeted Agents
  • Anti-CD20 Monoclonal Antibodies
• Small Molecule
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • PARP Inhibitors

Global Targeted Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-related Macular Degeneration
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)

Global Targeted Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Targeted Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (USA) (Acquired by Bristol-Myers Squibb)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations